Drug, bio-affecting and body treating compositions inventions 07/06

20060166858 - Bile-acid conjugates providing for sustained systemic concentration of drugs: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds....

20060166859 - Compounds and compositions for delivering active agents: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well....

20060166861 - Inclusion compound of porphyrin metal complex and albumin: where R1 is a cyclohexyl group or the like; R2 represents a substituent; M represents a transition metal atom or metal ion belonging to Groups 6 to 10 of the periodic table; X− represents a halogen ion; and the number of X− is obtained by subtracting 2 from a valence...

20060166863 - Inhibitor and stimulator of stem cell proliferation and uses thereof: Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation....

20060166864 - Methods for modulating telomerase activity: Disclosed herein are engineered zinc finger proteins which bind to telomeric structures; methods for their design, synthesis and use; and cells comprising a telomere-binding zinc finger protein. Methods for modulating telomerase activity using telomere-binding zinc finger proteins are also provided....

20060166862 - Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation: An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed....

20060166860 - Zinc transporter compositions for the treatment of cardiovascular diseases: The present invention relates to the use of ZnT-1, originally described as a zinc transporter, in the regulation of L-type calcium channels (LTCC). In this study, the inventors have unexpectedly demonstrated that ZnT-1 physically interacts with LTCC, regulating its function. Most importantly, the inventors have shown that ZnT-1 can regulate...

20060166866 - Cell adhesion inhibitors: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and...

20060166865 - Methods and compositions for treating flaviviruses and pestiviruses: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided....

20060166867 - Novel conjugates of polysaccharides and uses thereof: Novel conjugates composed of a saccharide-containing moiety (e.g., aminoglycosides) covalently linked to a moiety containing two or more basic amino acid residues (e.g., a polyarginine) and processes of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses of these conjugates as antiviral and antibacterial agents....

20060166869 - Novel use of lipopeptide preparations: The invention relates to the use of lipopeptide preparations as anti-tilted-peptide agents, which are able to inhibit or limit the destabilization effect of tilted peptides on hydrophobic/hydrophilic interfaces, for instance on membranes. The lipopeptides include surfactins, iturins, and fengycins. The invention also relates to a process for the production of...

20060166868 - Vegf peptides and their use: A novel peptide having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form, is proposed for use in therapy....

20060166886 - Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed....

20060166880 - Control of function of intracellular ca ion: Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+...

20060166876 - Delocalization molecules and use thereof: The invention relates to delocalization molecules, methods for the production thereof, and the use thereof as medicaments, especially for treating tumors....

20060166872 - Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia: A method of treating or preventing menorrhagia in an female individual the method comprising administering to the individual at least one agent that prevents PGP2α having its effect on the FP receptor. Optionally, an inhibitor of PGES and/or an antagonist of EP2 or EP4 is also administered....

20060166874 - Fvii or fviia variants having increased clotting activity: The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention...

20060166882 - Liquid, aqueous pharmaceutical composition of factor vii polypeptides: The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by...

20060166871 - Medical compositions containing ghrelin: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to...

20060166881 - Membrane-permeant peptide complexes for treatment of sepsis: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided....

20060166887 - Method of inducing neuronal production in the brain and spinal cord: The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain....

20060166877 - Methods of protecting against radiation damage using alpha thymosin: Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide....

20060166883 - Novel antimicrobial peptides based on tripeptide repeats: The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof...

20060166878 - Peptide antagonists of vascular endothelial growth factor: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and...

20060166873 - Preventive/remedy for arteriosclerosis: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of...

20060166884 - Purified rhlgf-i/rhlgfbp-3 complexes and their method of manufacture: Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I/IGFBP-3 complexes....

20060166875 - Single chain recombinant t cell receptors: A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus...

20060166885 - Treatment and prevention of decubitus: Provided is a method for treating a subject suffering from, or at risk of suffering from, decubitus, the method comprising a step of administering erythropoietin (EPO), or a functional part, derivative or analogue thereof to the subject. In certain embodiments, the EPO has been recombinantly produced in host cells that...

20060166879 - Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders: A method and formulation are provided for the treatment of medical conditions associated with the formation and/or deposition of macromolecular aggregates, particularly those associated with adverse ocular conditions. The formulation contains a non-cytotoxic chelating agent containing at least three negatively charged chelating atoms and a charge-masking agent containing at least...

20060166870 - Treatment of glioblastoma with thymosin-alpha 1: Thymosin-α1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma....

20060166888 - Leukocyte stimulating peptides: The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release....

20060166889 - Insulin conjugates and methods of use thereof: The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes....

20060166891 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia: The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases....

20060166890 - Non-t cell binding peptides and their uses: The present invention provides a non-T cell binding peptide and its analogs used for the treatment of rheumatoid arthritis. The polypeptide therapeutic agent can specifically inhibit abnormal immune responses of the rheumatoid arthritis, and fundamentally control the progression of this disease with effect on the initiating factor of the disease...

20060166892 - Treatment of cell proliferative disorders with chlorotoxin: Disclosed is a method of treating cell proliferative disorders, such as cancer, with low doses of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to inhibit or arrest abnormal cell growth....

20060166894 - Ace-inhibitors having antioxidant and no-donor activity: Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders....

20060166893 - Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments: with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following...

20060166896 - Novel indazole peptidomimetics as thrombin receptor antagonists: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of...

20060166897 - Novel indazole peptidomimetics as thrombin receptor antagonists: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of...

20060166895 - Retroviral protease inhibitors: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease....

20060166898 - Fertilizer-compatible composition: This invention relates to compositions compatible with liquid fertilizers and methods of use thereof....

20060166901 - Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids: The embodiments described herein include a composition and method of treatment using compositions that include at least one O-acetylsalicyl derivative. The compositions and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems....

20060166902 - Derivative of glucose and of vitamin f, compositions comprising it, uses and preparation process: An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for...

20060166899 - Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and...

20060166900 - Salt of morphine-6-glucuronide: Hydrobromide salt of morphine-6-β-D-glucuronide (M6G.HBr), a medicament, and a pharmaceutical composition comprising the M6G.HBr are disclosed. Methods of treating diseases using M6G.HBr, use of M6G.HBr as a medicament, in particular as an analgesic, are provided. Methods of making M6G.HBr and pharmaceutical compositions comprising the M6G.HBr also are provided....

20060166903 - Phosphocholine linked prodrug derivatives: Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and...

20060166904 - 9a-azalides with anti-inflammatory activity: Macrolides with anti-inflammatory activity are described, and more particularly, 9a-azalides without cladinose in position 3 with anti-inflammatory activity, their pharmaceutically acceptable salts and pharmaceutical compositions that contain them as active principle....

20060166905 - Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale: The invention relates to the use of Aivlosin for the treatment, prevention or control of diseases due to Brachyspira pilosicoli in pigs and Ornithobacterium rhinotrachelae in poultry....

20060166906 - 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance: e

20060166907 - Composition for the treatment of nasopharyngeal carcinoma and method of use thereof: Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracyline....

20060166916 - Composite polynucleic acid therapeutics: Compositions comprising therapeutic polynucleic acids and methods of use. The compositions comprise one or more polynucleic acids sequences having two or more features useful for treating diseases associated with cellular proliferation or growth....

20060166911 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a): The invention provides a human PDE11A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central...

20060166917 - Differentiation and/or proliferation modulating agents and uses therefor: The present invention discloses methods for modulating the differentiation and/or proliferation of mammary cells, especially of mammary epithelial cells, or for modulating the differentiation and/or proliferation of the lobuloalveolar system, or for modulating mammopoiesis and/or lactogenesis, or for modulating tumorigenesis in a cell which is associated with the reproductive system...

20060166924 - Gene therapeutics: Gene therapeutics to be used in treating diseases showing sensitivity to gene therapy, characterized by containing as the active ingredient an efficacious amount of a functional substance which has a function of having an affinity for a virus containing a gene usable in the gene therapy and another function of...

20060166915 - Human coagulation factor vii polypeptides: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment....

20060166923 - Immune stimulating composition comprising bacterial chromosomal dna fragments having methylated cpg sequences and non-toxic lipopolysaccharides: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant....

20060166914 - Method of nucleic acid infusion: A method of nucleic acid infusion, comprising the step (a) of bringing a nucleic acid, a hypertonic solution and cells into contact with each other and the step (b) of lowering the osmotic pressure of the hypertonic solution after the step (a). There is further provided a reagent for nucleic...

20060166908 - Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof: where A represents a direct bond, an alkylene group having 1 to 4 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1, R2, R3 and R4 each represent a hydrogen atom, a protective group for an amino group, a protective group for a...

20060166920 - Oligonucleotide based therapeutics: The present invention relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA,...

20060166909 - Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof: Oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase (MBD2/dMTase) are provided. The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumour cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target...

20060166922 - Polynucleotides targeted against the extended 5'-utr region of argininosuccinate synthase and uses thereof: The present invention is based in part on the discovery that the upstream open reading frame (uORF) in the extended 5′-untranslated region (5′-UTR) argininosuccinate synthase (AS) mRNA species is functional, and when functional, limits overall AS expression as well as nitric oxide (NO) production. Thus, the extended 5′-UTR AS mRNA...

20060166913 - Process for producing sirna: It is an object of the present invention to develop an inexpensive and simple method for transcription and synthesis of siRNA. The present invention provides an oligonucleotide, which at least comprises, in a direction from the 5′-terminus to the 3′-terminus: (1) an antisense sequence of a target nucleic acid sequence;...

20060166910 - Rna-interference by single-stranded rna molecules: The present invention relates to sequence and structural features of single-stranded (ss) RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation....

20060166919 - Rnai inhibition of ctgf for treatment of ocular disorders: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention....

20060166918 - Rnai modulation of mll-af4 and uses thereof: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides....

20060166921 - Rnai modulation of rsv and therapeutic uses thereof: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based...

20060166912 - Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy: The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic...

20060166925 - Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compou: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound...

20060166926 - Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases: The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions....

20060166927 - Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same: in which X is a divalent spacer group that is sufficiently long to allow the two oligosaccharide fragments A and B to each bind to one of the peptide sequences 125 to 143 of the C-terminal ends of a γ-interferon (γ-IFN) homodimer, n represents an integer from 0 to 10,...

20060166928 - Hyaluronic acid derivative gel and method for preparing the same: The present invention relates to a hyaluronic acid derivative gel, obtained by amidation of a hyaluronic acid, or its cationic salt, and an amine group-containing saccharide compound, having excellent viscoelastic properties, and a method for preparing it. Especially, the hyaluronic acid derivative gel according to the present invention shows responses...

20060166930 - Medicinal composition for ophthal use containing acetylated hyaluronic acid: The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition...

20060166929 - Sugar-chain asparagine derivatives and processes for the preparation thereof: an asparagine-linked oligosaccharide derivative containing at least one fucose in N-acetylglucosamine on the nonreducing terminal side of an asparagine-linked oligosaccharide wherein the amino group of asparagine is modified with a biotin group or FITC group, a microplate having immobilized thereto a biotinated asparagine-linked oligosaccharide, and an affinity column having immobilized...

20060166931 - Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof: The present invention relates to the inclusion complexes of butylphthalide, which is D,L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin, in order to increase the...

20060166932 - Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second...

20060166933 - Novel 2h-chromene derivatives as selective estrogen receptor modulators: The present invention is directed to novel 2H-chromene derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more estrogen receptors and processes for their preparation....

20060166934 - Composition comprising phytosphingosine derivatives for apoptosis induction: The present invention is related to compositions for the induction of apoptosis containing phytosphingosine derivatives as effective components. The present invention is related to compositions for the induction of apoptosis containing Vit D3 or calcipotriol as an effective component in addition to phytosphingosine derivatives. The compositions of the present invention...

20060166935 - Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction: This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's...

20060166936 - Diaminotriazole compounds useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders....

20060166937 - Bisphosphonates for the treatment of atherosclerosis and device comprising them: A method for the treatment of atherosclerosis, in particular atherosclerotic/valve calcification and plaque rupture/stroke, in a patient in need of such treatment, e.g. a patient with aterial or valve calcification, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient....

20060166938 - Method of treatment using bisphosphonic acid: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficacious daily dose of a bisphosphonic acid or a pharmaceutically...

20060166939 - Fertilizer-compatible composition: This invention relates to pesticidal compositions compatible with liquid fertilizers and methods of use thereof....

20060166940 - Amino-propanol derivatives: i

20060166941 - Treatment and/or prevention of non-viral epithelial damage: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic...

20060166942 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4....

20060166943 - Microbicidal pyrimidine or triazine for preventing sexual hiv transmission: A present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans....

20060166944 - 4-aminotetracyclines and methods of use thereof: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression....

20060166946 - Methods of preparing substituted tetracyclines with transition metal-based chemistries: The present invention relates to novel chemistries which allow for heretofore unobtainable substituted tetracycline compounds which exhibit significant antibacterial activity. The methods disclosed herein utilize reactive tetracycline-based precursor compounds, reactive organic substituent precursors and transition metal catalysts under conditions such that a tetracycline compound substituted with the desired organic substituent...

20060166945 - Substituted tetracycline compounds: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression....

20060166947 - Multiple myeloma treatments: Provided herein are methods for treating refractory or resistant multiple myeloma in a subject using indole derivatives....

20060166948 - Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries: Vitamin K is effective in counteracting the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided)...

20060166949 - Vitamin d analogues, compositions comprising said analogues and their use: t

20060166951 - Compositions and methods for sterol isolation and purification: Compositions and methods for isolating and purifying sterols, stanols, policosanols, and other organic molecules of interest are disclosed. The compositions encompass purified sterols comprising, for example, policosanols. Methods comprise solvent extraction of sterols from any solute comprising sterol-containing material. Such sterol-containing material may be in the form of plant material...

20060166950 - Treatment of neovascularization disorders with squalamine: Aminosterol compounds are described that are useful as inhibitors of the sodium/proton exchanger (NHE). Methods of using such aminosterols compounds are also enclosed, including those employing compounds that are inhibitors of a spectrum of NHEs as well as those using compounds that are inhibitors of only one specific NHE. Advantageous...

20060166952 - 2\"oxo-voruscharin and derivatives thereof: 2″oxo-voruscharin compound and derivatives thereof are disclosed as well as pharmaceutical compositions which include 2″oxo-voruscharin compound or derivatives thereof. The disclosed 2″oxo-voruscharin compound and its derivatives are useful for cancer treatment. Methods of treating cancer using the disclosed compounds are also disclosed....

20060166953 - Ciclesonide-containing sterile aqueous suspension: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving, as well as methods of manufacturing a ciclesonide-containing sterile aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension....

20060166954 - Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described....

20060166955 - Production process for 16-dehydropregnenoneol and its analogs: The present invention relates to a clean process for the degradation of steroidal sapogenin to produce 16-dehydropregnenolone and its analogs. The pure or the crude pseudo steroidal sapogenin, derived from steroidal sapogenin, dissolved in organic solvent, reacts with hydrogen peroxide with or without metal compound and acid as catalyst, and...

20060166956 - Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration: The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration....

20060166957 - Methods of treating obesity and related disorders using tellurium selenium compounds: The present invention relates to methods of using tellurium and selenium containing compounds, and particularly to the use of small organic molecules containing tellurium or selenium as exemplified by the compound ammonium-trichloro(dioxoethylene-O,O′)tellurate (known by the abbreviation AS101) for treating obesity and obesity related disorders or complications and for reducing of...

20060166958 - Crystalline amoxicillin trihydrate powder: The invention relates to crystalline amoxicillin trihydrate powder having a bulk density higher than 0.45 g/ml. The invention also relates to a process for preparing crystalline amoxicillin trihydrate powder, said process comprising: crystallizing amoxicillin trihydrate from a solution containing dissolved amoxicillin; separating the crystals from said solution; and drying the...

20060166959 - Pharmaceutical compositions based on azetidine derivatives: e

20060166962 - N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines: It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is...

20060166961 - Cell adhesion inhibitors:

20060166960 - Imidazole and benzimidazole derivatives useful as histamine h3 antagonists: and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I; also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of Formula I, as well as combinations with other drugs useful...

20060166963 - Processes for producing 4-aminoquinazolines: d

20060166964 - Inhibitors of hcv replication: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds....

20060166965 - Atypical antipsychotic agents having low affinity for the d2 receptor: d

20060166966 - 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis: This invention relates to compounds of formula (I) which are cysteine protease inhibitors, in particular, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis....

20060166968 - Crystalline form of oxcarbazepine: Crystalline form F of oxcarbazepine....

20060166967 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain: The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 %...

20060166969 - Ampa antagonists for the treatment of dizziness, including vertigo and meniere's disorder: e

20060166971 - Benzamide derivatives as oxytocin agonists and vasopressin antagonists: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea....

20060166970 - Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses...

20060166972 - Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator: An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome,...

20060166974 - Azabenzoxazoles for the treatment of cns disorders: The present invention relates to α7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) such as cognitive deficits in schizophrenia, by administering to a mammal an α7 nicotinic receptor agonist of formula I as shown herein....

20060166976 - Compositions and methods for treating or preventing convulsions or seizures: The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefore. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially...

20060166975 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation...

20060166973 - Organic compounds as agents for the treatment of aldosterone mediated conditions: provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula I may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular,...

20060166977 - Antibacterial agents: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans....

20060166978 - Substituted beta carbolines: i

20060166979 - New oxabispidine compounds useful in the treatment of cardiac arrhythmias:

20060166980 - New oxabispidine compounds useful in the treatment of cardiac arrhythmias:

20060166981 - Novel compounds for use in weight loss and appetite suppression in humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy...

20060166984 - Amino substituted benzo(hetero)cyclic derivatives: Use of compounds Formula (I), A=a 5- to 7-membered ring which may contain 1-3 heteroatoms and which may be saturated or partially or completely unsaturated; R1═OH, SH, NH2, CN, NO2, halogen, C1-C6-alkyl, C1-C6-haloalkyl; C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C2-C6-alkenyl, C2-C6alkenyloxy, C2-C6-alkenylthio, C2-C6-alkynyl, C2-C6-alkynyloxy, C2-C6-alkynylthio, C1-C6-alkylsulfonyl, C1-C6-alkylsulfoxyl, C2-C6-alkenylsulfonyl, C2-C6-alkylsulfoxyl, C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-aklylcarbonyloxy;...

20060166983 - Indole derivatives as ppar modulators: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are...

20060166982 - Isotopically labelly indlinone derivatives and process for their preparation: Compounds which are isotopically labeled carbonium 14 [14C] indolinone derivatives and process for their preparation are disclosed; these compounds are useful for absorption, distribution, metabolism and excretion (ADME) studies....

20060166985 - Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated....

20060166988 - Novel compounds: The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred....

20060166986 - Novel stereoselective synthesis of benzimidazole sulfoxides: The present invention relates to a process for stereoselective synthesis of substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol is reacted with (R)-camphorsulfonyl chloride to form a mixture of 1-(R)-camphorsulfonyl-5-(and 6-)methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-1H-benzimidazole, oxidized to obtain a diastereomeric excess of 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole over 1-(R)-camphorsulfonyl-(5-...

20060166987 - Opioid receptor antagonists: A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed....

20060166989 - 2-naphthamide derivatives: The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder...

20060166990 - Novel aminobenzophenone compounds: The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer....

20060166991 - Pyridine carboxamide derivatives and their use as pesticides: e

20060166992 - Heterocyclically substituted imidazotriazines: The invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia....

20060166993 - Substituted imidazotriazines: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia....

20060166994 - Method for treating renal failure: Levosimendan or its active metabolite (II), which have been previously suggested for the treatment of congestive heart failure, are useful in the treatment of renal failure....

20060166997 - Phenylglycinamide derivatives useful as anticoagulants: The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or...

20060166996 - Phthalazine derivatives as phosphodiesterase 4 inhibitors: Compounds of formula I wherein R and R1 are as defined in the description. The compounds of formula I are PDE 4 inhibitors....

20060166995 - Piperidine-n-oxide-derivatives: m

20060166998 - Pyrrolo[1,2-b]pyridazine compounds and their uses:

20060166999 - Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl): The invention relates to the use of inhibitors of the microsomal triglyceride transfer protein (MTP) for reducing the number of postprandial triglyceride-rich lipoprotein particles (ppTRL) or for reducing their decomposition products i.e. the cholesterol-rich ‘small remnant particle’ (remnants). Said particles are associated with apolipoprotein B-48 (ApoB-48) and are designated as...

20060167000 - Neurologically-active compounds: The present invention relates to neurologically-active compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease....

20060167001 - Pyridazinone-derivatives as pde4 inhibitors: e

20060167002 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists: The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I), wherein X is CH2 or a single bond; Y is a group of formula (II, III, IV) and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes...

20060167003 - Probucol derivatives: Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases....

20060167004 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060167005 - New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine: (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions....

20060167006 - Method of treatment: A method of treating a warm-blooded animal suffering from pancreatic cancer which. comprises administering to said animal in need of such a treatment a dose, effective against said disease, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof....

20060167007 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof: m

20060167008 - Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists: In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK1 receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of...

20060167009 - Monocyclic substituted phenyl methanones:

20060167010 - Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds: the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond. Most preferably, R3 and R4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond, such that the chemical backbone of the...

20060167011 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products...

20060167012 - Sulfonyl-substituted bicyclic compounds as modulators of ppar: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed....

20060167013 - Inhibitors for excessive accumulation of sodium ion in cells: A medicament for suppressing intracellular excess accumulation of sodium ions and a medicament for therapeutic and/or preventive treatment of cardiac disorders resulting from cardiosurgery operations which comprises an aminobenzenesulfonic acid derivative represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof...

20060167014 - Piperazine compounds and medicinal use thereof: wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen,...

20060167015 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy...

20060167016 - 2,5-disubstituted pyrimidine derivatives: The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases....

20060167019 - Fungicidal mixtures based on a trizolopyrimidine derivative: e

20060167017 - Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungl, and agents containing said fungicadal triazolopyrimidines:

20060167018 - Synergistically acting herbicidal mixtures: A synergistic herbicidal mixture comprising A) picolinafen; or one of its environmentally compatible salts; and B) a synergistically effective amount of at least a triazolopyrimidine herbicide selected from the triazolopyrimidine sulfonanilides and penoxsulam; or one of its environmentally compatible salts or esters; and, if desired, C) at least a safener....

20060167021 - Inhibition of src for treatment of reperfusion injury related to revascularization: The present invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability....

20060167022 - Method of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and...

20060167020 - Pyrazolopyrimidines as kinase inhibitors: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds....

20060167023 - Substituted phenyl methanones: e

20060167024 - Cancer combination therapy comprising azd2171 and zd1839: The present invention elates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060167025 - Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs: e

20060167027 - Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060167026 - Antipsychotic molecular-targeting epithelial growth factor receptor: The purpose of this invention is to provide an agent useful for prevention and/or treatment of psychosis, schizophrenia and cognitive impairments. To solve this problem, this invention provides epidermal growth factor receptor inhibitors as therapeutic agents for psychosis, schizophrenia and cognitive impairments....

20060167029 - Mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and...

20060167028 - Nicotine in therapeutic angiogenesis and vasculogenesis: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease....

20060167030 - Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof: e

20060167031 - Method of administrating an anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor: The present invention relates to a method for treating a cancer comprising orally administering a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in...

20060167032 - Pharmaceutical composition and method for treating disorders of the central nervous system: Disorders of the ventral nervous system (CNS) are treated by the administration of a GABA analog such as gabapentin or pregablin, an NMDA receptor antagonist such as dextromethorphan or d-methodone and, optionally, another pharmacologically active substance, e.g., one which is effective for the treatment of a CNS disorder....

20060167033 - 7-imino derivatives of camptothecin having antitumor activity: s

20060167034 - Novel benzonaphthyridines:

20060167035 - Quinoline derivative, its use, production and pharmaceutical agents containing the latter:

20060167036 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts,...

20060167037 - Combinational radiotherapy and chemotherapy compositions and methods: This invention relates to combination therapies involving radiotherapy and chemotherapy. In particular the invention relates to the use of isoflavones or analogues thereof in combination with radiotherapy or chemotherapy in the treatment of cancer and related diseases and conditions. The invention also relates to compositions and agents useful for same...

20060167038 - Pyrrolopyridine derivative and use thereof: wherein Ring A represents an optionally substituted pyridine ring; X represents an electron-attracting group; Y represents an optionally substituted divalent C1-6 chain hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; and R2 and R3 each independently represents hydrogen, an optionally substituted hydrocarbon group or an optionally-substituted heterocyclic group, or...

20060167039 - Nicotinic alpha-7 receptor ligands and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7...

20060167041 - Imidazopyridine compound: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom,...

20060167040 - Pyrazolopyridine derivates: New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors....

20060167042 - Quinuclidine amide derivatives: New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors....

20060167043 - Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same: w

20060167044 - Piperidine derivatives and their use as anti-inflammatory agents:

20060167045 - Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist: The present invention relates to the treatment of hypertension and type 2 diabetes, Metabolic Syndrome or a pre-diabetic state, by the administration of a therapeutically effective amount of a combination of a dual PPARα/γ agonist and an Angiotensin II type I receptor antagonist, including pharmaceutically acceptable salts and solvates of...

20060167046 - Histamine h3 receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat...

20060167047 - Tetrahydorquinoline derivatives and their use as fsh receptor modulators: The present invention relates to tetrahydroquinoline derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are H, Me; R3 is (2-6C)heterocycloalkyl(1-4C)alkyl, (2-5C)heteroaryl(1-4C)alkyl, (6C)aryl (1-4C)alkyl, (1-4C)(di)alkylaminocarbonylamino(2-4C)alkyl, (2-6C) heterocycloalkylcarbonylamino(2-4C)alkyl, R5-(2-4C)alkyl or R5-carbonyl(1-4C)alkyl; R4 is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-6C) alkyl and R5 is (di)(1-4C)alkylamino, (1-4C)alkoxy,...

20060167048 - N-4-piperidinyl compounds as ccr5 modulators: The invention provides a compound of formula (I): [Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and...

20060167050 - Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder: The present invention relates to the combined use of methyl phenidate and at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof in the treatment of attention deficit hyperactive disorder (ADHD). Methylphenidate and melatonin or its analogue may be used together or in combination with one...

20060167049 - Terphenly derivatives, preparation thereof, compositions containing same: e

20060167051 - Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride: The present invention relates to crystalline non-solvated 1-(4-2-piperidinylethoxy)phenoxy)-2-(4-methane-sulfonylphenyl)-6-hydroxynaphthalene hydrochloride, useful as a selective estrogen receptor modulator....

20060167053 - Heteroarylcarbamoylbenzene derivative: e

20060167052 - Piperidine derivative, process for producing the same, and use: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino...

20060167054 - Immunomodulation with novel pharmaceutical compositions: e

20060167055 - Non-nucleoside reverse transcriptase inhibitors: A compound of the formula (Y): where; R1 is O, S; R2 is a nitrogen-containing heterocycle; R3 is H, C1-C3 alkyl; X is —(C8R8)n-D-(C8C8′)m—; D is a bond, —NR9—, —O—, —S—, —S(═O)— or —S(═O)2; n and m are independently 0, 1 or 2, R8 and R8′ are independently H, C1-C3...

20060167057 - Compounds for the treatment of cns and amyloid associated diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease....

20060167056 - Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl)-4-methyl-pyridin-3-ylmethyl}-ethyl-amine: The present invention relates to novel polymorphic forms of of 3{5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity....

20060167058 - Ppar-activating compound: wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a...

20060167059 - Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1): wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or...

20060167062 - Enema preparation: e

20060167061 - Novel process to prepare pioglitazone via several novel intermediates: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine....

20060167063 - Process for the manufacture of isradipine: The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole-4-carboxaldehyde with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. To obtain the product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester which is then reacted with isopropyl-β-aminocrotonate...

20060167060 - Pyrazole and pyrrole carboxamide insecticides: This invention provides compounds of Formula (I), N-oxides and salts thereof wherein: A is O or S; B is a phenyl ring or a pyridine ring, each ring optionally substituted with 1 to 5 R; J is a pyrazole or a pyrrole heterocyclic ring system as defined herein; and; R1...

20060167064 - Pharmaceutical liquid composition containing pyridone derivative: A pharmaceutical liquid composition containing the Pirfenidone in a very high concentration of more or less 25% by weight can be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether. Even when the liquid medicinal compositions are stored for a long period of time, the Pirfenidone will not be...

20060167066 - Pyrrolidine inhibitors of iap: p

20060167065 - Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions....

20060167067 - Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent: wherein each R independently represents a hydrogen atom, a lower alkyl group, an aryl group, an allyl group, an aralkyl group, a halogen atom, a hydroxyl group, an amino group, R′O—, R′(C═O)—, R′(C═O)O—, or R′O(C═O)—, wherein R′ is an alkyl group containing 1 to 5 carbon atoms, or a pharmaceutically...

20060167068 - Method of treating self-injurious behavior with glutamate modulating agents: Inventors have made the surprising discovery that glutamate modulating agents are useful for treating borderline personality disorder and self-injurious behavior. Methods of treating borderline personality and self-injurious behavior are provided herein by administering a glutamate modulating agent to a patient are included herein. The invention also includes combination methods of...

20060167069 - Pharmaceutical composition of metaxalone with enhanced oral bioavailability: The present invention provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the pharmaceutical composition has enhanced oral bioavailability. The present invention also provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the extent of absorption of metaxalone is independent of whether...

20060167070 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising...

20060167071 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167072 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167073 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167074 - Methods and compositions for the treatment of psychiatric disorders: A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor or prodrug thereof to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or depressive disorders, is disclosed...

20060167075 - Modulators of faah: Methods for inhibiting the activity of FAAH and methods for preventing and/or treating certain disorders, e.g., anxiety disorders, sleep disorders and weight disorders, by administering celecoxib, valdecoxib or certain structurally related compounds at a dosage that is sufficient to treat and/or prevent the disorder are described....

20060167076 - Acutumine and acutumine compounds synthesis and use: t

20060167077 - Process for preparation of carvedilol: The invention solves a new method of preparation of Carvedilol for pharmaceutical use. In the synthesis of Carvedilol a reaction of 4-(oxirane-2-ylmethoxy)-9H-arbazole (II) with 2-(2-methoxyphenoxy)ethylamine salts (IV) in the presence of a base, in an alcohol having the number of carbons C2 to C5 as a solvent, at an elevated...

20060167079 - Pyrrolidine -2-ones as factor xa inhibitors: e

20060167078 - Substituted benzodioxepins: Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition. They can be employed...

20060167080 - Wortmannin analogs and methods of using same: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein....

20060167081 - Ep4 receptor agonists: This invention relates to potent selective agonists of the EP, subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of...

20060167082 - Nitrate esters of phenylaminothiophenacetic acid derivatives: i

20060167084 - Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis: Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse....

20060167083 - Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures: Methods for the treatment of diseases associated with aberrant cell survival, aberrant cell proliferation, abnorm